INIBO-Injection to reduce fine lines and wrinkles
INIBO, 100% purity of BoNT Type A Pharmaceutical has the best value in terms of its price and quality.
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Brand name
- INIBO
- Payment Terms
- T/T
- Production method
- Available
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- filler, medical aesthetics, toxin
- Category
- Other Pharmaceuticals
Inibio co., ltd.
South Korea
- Verified Certificate
-
3
| Product name | INIBO-Injection to reduce fine lines and wrinkles | Certification | - |
|---|---|---|---|
| Category | Other Pharmaceuticals | Material | BONT |
| Keyword | filler , medical aesthetics , toxin | Unit Size | 47.0 * 67.0 * 38.0 mm |
| Brand name | INIBO | Unit Weigh | 60 g |
| origin | South Korea | Stock | 50000 |
| Supply type | Available | HS code | 300290 |
Product Information
We are Inibio, a company established in 2017 that specializes in developing and manufacturing botulinum toxin products.
We value advanced technology & challenge above all else and seek to continually grow & dynamically challenge new markets in the field of medical aesthetics.
We are currently expanding our export efforts globally. We actively seek out opportunities to mutually grow business models together, and welcome collaborations. Feel free to contact us – we eagerly wait for your inquiries
Inibio was established in September 2017. though it has been only 5 years, we have done a lot of work and still go forward.
First is the cGMP-grade production facility. it is a 7th-floor building located nearby Seoul and the international airport enables us to export. We already got kGMP.
Moreover, from the beginning, we set our facility following the global standard for USA FDA & Europe EMA. It is thanks to our experts in each department such as manufacturing, R&D, QC..
They already have experienced the whole process such as development, and FDA approval. so we got it done quickly and can make the next step go fast.
In July 2023, we received approval for the kFDA. so we are concentrating on entering the global countries
l cGMP grade production facilities->High quality.
l Free Sales Certificate approved kFDA(Ministry of Food and Drug Safety)
l Validation of strains by the world's leading authority->Original strain(No strain issue).
l 100% purity of 900kDA protein-> Fast on set time & Zero side effect in diffusion
l Vacuum-drying method same as Allergan’s Product
l Phase 1/2, 3 clinical trial in Korea completed
l Completed NDA for kFDA -> Plan to launch in Korean Market end of 2023
Name of Drug: INIBO inj. 100 UNITS
Pharmaceutical Dosage Form: Powder for solution for injection
Strength: 100 Units
Pack size S: 47 x 38 x 67 mm, 1 vial/box
M: 199 x 99 x 73 mm, 10 ea/box
L: 515 x 415 x 165 mm, 200 ea/box
STORAGE: Unopened vials of INIBO inj. should be stored in a refrigerator 2° to 8°C (36º to 46ºF). Do not use after the expiration date on the vial.
B2B Trade
| Price (FOB) | Negotiable | transportation | Air Transportation |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | T/T | Shipping time | Negotiable |
- President
- KIM CHEONG SE
- Address
- 2F Gonghangdaero 248, Gangseo-gu, Seoul, Korea
- Product Category
- Other Pharmaceuticals
- Year Established
- 2017
- No. of Total Employees
- 101-500
- Company introduction
-
Inibio was established in September2017 to develop, manufacture, sell, and export biomedicine products. Our goalis to be a global expert providing total medical aesthetic solutions withproducts including botulinum toxins, hyaluronic acid fillers, and other DDSproducts.
During our first seed step, 3 years,we have done a lot of works to develop the main pipeline, botulinum toxin typeA, and continue to go on our journey.
We have cGMP grade productionfacility, which is designed to apply to International Standard, USA FDA, andEMA. Its annual production capacity is 2millions vials and it will be extendedto 6millions vials by 2022.
About approval, we have already got an export license (FSC)Currently, a patient injection was completed for the third phase clinical test.This is for 292 patients and it was 3 weeks ahead of the original schedule. So,we assure you that our first product, Inibo will be released in the second halfof next year in the Korean market.
- Main Markets
-
China
- Main Product
- Attached File
Related Products
G2ON Synbiotics Lactobacillus Probiotics
HAN SAN Hand Sanitizer 500ml / Anti Bacteria / Disinfectant
Mumus Guard Plus Mosquito Repellent for All Family Members
Multivita injection
Elitox®
